including the development, production and supply of diagnostic and therapeutic radiopharmaceuticals and radioisotopes.
View moreRelying on a global supply chain system, we can continue to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new radionuclide generators, which can effectively alleviate the shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can continue to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new radionuclide generators, which can effectively alleviate the shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, and innovations in products and technologies will redefine the next generation of radiopharmaceuticals
View more
NorthStar is poised to be the first commercial-scale producer of rare radioisotope, in chronic short supply, for use in clinical studies and patient healthcare to treat many types of cancer
View moreOntario invests $6.8 million to expand McMaster’s nuclear capacity
PSMA PET Improves Decision Making for Prostate Cancer Treatment
New Compact and Low-Cost Lensless Radiomicroscope Developed for Nuclear Medicine Imaging
Defence Therapeutics and Orano agree to collaborate on radio-immuno-conjugates
New Compact and Low-Cost Lensless Radiomicroscope Developed for Nuclear Medicine Imaging
Immuno-PET predicts patient response to rituximab therapy
